• Boston "Best of ASCO meeting set for July.
• Boston pediatric oncology meeting organizers hold court at Dana Farber booth
• Also, Dana Farber doc Pasi A. Janne comments on much-touted Pfizer lung cancer trial of 82 patients in today’s NY Times

.

Even though the clinical trial was small (just 82 people, with no control group), the results were considered so striking for such sick patients that the study will be featured Sunday at the main session of the annual meeting of the American Society of Clinical Oncology here.

“This is a phenomenal example of finding the right patient and the right drug very early on,” said Dr. Pasi A. Janne of the Dana-Farber Cancer Institute in Boston, who was involved in the trial.

We checked out Dr. Janne on the meeting’s 29-page " Faculty and Discussant Disclosure Index"

In addition to this Pfizer study, Dr. Janne note on the conference disclosure form tthat he consults with the following companies: Ariad, Boehringer, Ingelheim, Janssen-Cilag, Myriad Genetics, and Syndax Pharmaceuticals. He notes that his consulting for Pfizer is unpaid but that gets research support from the company